AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.130
-0.003 (-2.26%)
At close: Mar 10, 2025, 4:00 PM
0.135
+0.005 (3.92%)
After-hours: Mar 10, 2025, 7:57 PM EST
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $35.00K in the quarter ending September 30, 2024, a decrease of -23.91%. This brings the company's revenue in the last twelve months to $190.00K, down -1.55% year-over-year. In the year 2023, AIM ImmunoTech had annual revenue of $202.00K with 43.26% growth.
Revenue (ttm)
$190.00K
Revenue Growth
-1.55%
P/S Ratio
34.64
Revenue / Employee
$6,786
Employees
28
Market Cap
8.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
| Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
| Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
| Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
| Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
AIM News
- 10 days ago - AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - GlobeNewsWire
- 12 days ago - AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - GlobeNewsWire
- 12 days ago - AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - GlobeNewsWire
- 13 days ago - AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer - GlobeNewsWire
- 27 days ago - AIM ImmunoTech Releases Virtual Investor “What This Means Segment” - GlobeNewsWire
- 27 days ago - AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - GlobeNewsWire